Anti-inflammatory therapy with canakinumab for the prevention of hospitalization for heart failure

Circulation

Volumn 139, Issue 10, 2019, Pages 1289-1299

  Everett, Brendan M ^a   Cornel, Jan H ^b   Lainscak, Mitja ^c   Anker, Stefan D ^d   Abbate, Antonio ^e   Thuren, Tom ^f   Libby, Peter ^a   Glynn, Robert J ^a   Ridker, Paul M ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b Location Alkmaar   (Netherlands)

^c UNIVERSITY OF LJUBLJANA   (Slovenia)

^d CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^e VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^f NOVARTIS PHARMA AG   (Switzerland)

Author keywords

clinical trial publication type ; heart failure; inflammation

Indexed keywords

C REACTIVE PROTEIN; CANAKINUMAB; INTERLEUKIN 6; PLACEBO; ANTIINFLAMMATORY AGENT; AUTACOID; BIOLOGICAL MARKER; MONOCLONAL ANTIBODY;

ADULT; AGED; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CARDIOVASCULAR MORTALITY; CLINICAL ASSESSMENT; CONTROLLED STUDY; CORONARY ARTERY BYPASS SURGERY; DIABETES MELLITUS; FEMALE; HEART FAILURE; HEART INFARCTION; HOSPITALIZATION; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; BLOOD; CLINICAL TRIAL; DISEASE EXACERBATION; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; HOSPITAL ADMISSION; METABOLISM; MORTALITY; MULTICENTER STUDY; PATHOPHYSIOLOGY; PROSPECTIVE STUDY; PROTECTION; RISK FACTOR; TIME FACTOR; TREATMENT OUTCOME;

AGED; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL, HUMANIZED; BIOMARKERS; C-REACTIVE PROTEIN; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HEART FAILURE; HUMANS; INFLAMMATION MEDIATORS; MALE; MIDDLE AGED; PATIENT ADMISSION; PROSPECTIVE STUDIES; PROTECTIVE FACTORS; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 85062869193     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.118.038010     Document Type: Article

References (31)

1. Elster SK, Braunwald E, Wood HF, A study of C-reactive protein in the serum of patients with congestive heart failure. Am Heart J 1956 51 533 541
2. Testa M, Yeh M, Lee P, Fanelli R, Loperfido F, Berman JW, LeJemtel TH, Circulating levels of cytokines and their endogenous modulators in patients with mild to severe congestive heart failure due to coronary artery disease or hypertension. J Am Coll Cardiol 1996 28 964 971
3. Deswal A, Petersen NJ, Feldman AM, Young JB, White BG, Mann DL, Cytokines and cytokine receptors in advanced heart failure: An analysis of the cytokine database from the Vesnarinone Trial (VEST). Circulation 2001 103 2055 2059
4. Vasan RS, Sullivan LM, Roubenoff R, Dinarello CA, Harris T, Benjamin EJ, Sawyer DB, Levy D, Wilson PW, D'Agostino RB, Framingham Heart Study Inflammatory markers and risk of heart failure in elderly subjects without prior myocardial infarction: The Framingham Heart Study. Circulation 2003 107 1486 1491
5. Kardys I, Knetsch AM, Bleumink GS, Deckers JW, Hofman A, Stricker BH, Witteman JC, C-reactive protein and risk of heart failure: The Rotterdam Study. Am Heart J 2006 152 514 520. doi: 10.1016/j.ahj.2006.02.023
6. Kalogeropoulos A, Georgiopoulou V, Psaty BM, Rodondi N, Smith AL, Harrison DG, Liu Y, Hoffmann U, Bauer DC, Newman AB, Kritchevsky SB, Harris TB, Butler J, Health ABC Study Investigators Inflammatory markers and incident heart failure risk in older adults: The Health ABC (Health, Aging, and Body Composition) study. J Am Coll Cardiol 2010 55 2129 2137. doi: 10.1016/j.jacc.2009.12.045
7. Gulick T, Chung MK, Pieper SJ, Lange LG, Schreiner GF, Interleukin 1 and tumor necrosis factor inhibit cardiac myocyte beta-Adrenergic responsiveness. Proc Natl Acad Sci U S A 1989 86 6753 6757
8. Bozkurt B, Kribbs SB, Clubb FJ Jr, Michael LH, Didenko VV, Hornsby PJ, Seta Y, Oral H, Spinale FG, Mann DL, Pathophysiologically relevant concentrations of tumor necrosis factor-Alpha promote progressive left ventricular dysfunction and remodeling in rats. Circulation 1998 97 1382 1391
9. Tatsumi T, Matoba S, Kawahara A, Keira N, Shiraishi J, Akashi K, Kobara M, Tanaka T, Katamura M, Nakagawa C, Ohta B, Shirayama T, Takeda K, Asayama J, Fliss H, Nakagawa M, Cytokine-induced nitric oxide production inhibits mitochondrial energy production and impairs contractile function in rat cardiac myocytes. J Am Coll Cardiol 2000 35 1338 1346
10. Deswal A, Bozkurt B, Seta Y, Parilti-Eiswirth S, Hayes FA, Blosch C, Mann DL, Safety and efficacy of a soluble P75 tumor necrosis factor receptor (Enbrel, etanercept) in patients with advanced heart failure. Circulation 1999 99 3224 3226
11. Bozkurt B, Torre-Amione G, Warren MS, Whitmore J, Soran OZ, Feldman AM, Mann DL, Results of targeted anti-Tumor necrosis factor therapy with etanercept (ENBREL) in patients with advanced heart failure. Circulation 2001 103 1044 1047
12. Chung ES, Packer M, Lo KH, Fasanmade AA, Willerson JT, Anti-TNF Therapy Against Congestive Heart Failure Investigators Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-Alpha, in patients with moderate-To-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation 2003 107 3133 3140. doi: 10.1161/01.CIR.0000077913.60364.D2
13. Mann DL, McMurray JJ, Packer M, Swedberg K, Borer JS, Colucci WS, Djian J, Drexler H, Feldman A, Kober L, Krum H, Liu P, Nieminen M, Tavazzi L, van Veldhuisen DJ, Waldenstrom A, Warren M, Westheim A, Zannad F, Fleming T, Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation 2004 109 1594 1602. doi: 10.1161/01.CIR.0000124490.27666.B2
14. Mann DL, Innate immunity and the failing heart: The cytokine hypothesis revisited. Circ Res 2015 116 1254 1268. doi: 10.1161/CIRCRESAHA.116.302317
15. Mezzaroma E, Toldo S, Farkas D, Seropian IM, Van Tassell BW, Salloum FN, Kannan HR, Menna AC, Voelkel NF, Abbate A, The inflammasome promotes adverse cardiac remodeling following acute myocardial infarction in the mouse. Proc Natl Acad Sci U S A 2011 108 19725 19730. doi: 10.1073/pnas.1108586108
16. Van Tassell BW, Arena RA, Toldo S, Mezzaroma E, Azam T, Seropian IM, Shah K, Canada J, Voelkel NF, Dinarello CA, Abbate A, Enhanced interleukin-1 activity contributes to exercise intolerance in patients with systolic heart failure. PLoS One 2012 7 e33438. doi: 10.1371/journal.pone.0033438
17. Van Tassell BW, Canada J, Carbone S, Trankle C, Buckley L, Oddi Erdle C, Abouzaki NA, Dixon D, Kadariya D, Christopher S, Schatz A, Regan J, Viscusi M, Del Buono M, Melchior R, Mankad P, Lu J, Sculthorpe R, Biondi-Zoccai G, Lesnefsky E, Arena R, Abbate A, Interleukin-1 blockade in recently decompensated systolic heart failure: results from REDHART (Recently Decompensated Heart Failure Anakinra Response Trial). Circ Heart Fail 2017 10 e004373. doi: 10.1161/CIRCHEARTFAILURE.118.005036
18. Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, Ballantyne C, Fonseca F, Nicolau J, Koenig W, Anker SD, Kastelein JJP, Cornel JH, Pais P, Pella D, Genest J, Cifkova R, Lorenzatti A, Forster T, Kobalava Z, Vida-Simiti L, Flather M, Shimokawa H, Ogawa H, Dellborg M, Rossi PRF, Troquay RPT, Libby P, Glynn RJ, CANTOS Trial Group Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med 2017 377 1119 1131. doi: 10.1056/NEJMoa1707914
19. Zannad F, Garcia AA, Anker SD, Armstrong PW, Calvo G, Cleland JG, Cohn JN, Dickstein K, Domanski MJ, Ekman I, Filippatos GS, Gheorghiade M, Hernandez AF, Jaarsma T, Koglin J, Konstam M, Kupfer S, Maggioni AP, Mebazaa A, Metra M, Nowack C, Pieske B, Piña IL, Pocock SJ, Ponikowski P, Rosano G, Ruilope LM, Ruschitzka F, Severin T, Solomon S, Stein K, Stockbridge NL, Stough WG, Swedberg K, Tavazzi L, Voors AA, Wasserman SM, Woehrle H, Zalewski A, McMurray JJ, Clinical outcome endpoints in heart failure trials: A European Society of Cardiology Heart Failure Association consensus document. Eur J Heart Fail 2013 15 1082 1094. doi: 10.1093/eurjhf/hft095
20. Anand IS, Latini R, Florea VG, Kuskowski MA, Rector T, Masson S, Signorini S, Mocarelli P, Hester A, Glazer R, Cohn JN, Val-HeFT Investigators C-reactive protein in heart failure: prognostic value and the effect of valsartan. Circulation 2005 112 1428 1434. doi: 10.1161/CIRCULATIONAHA.104.508465
21. Lin DY, Wei LJ, Ying Z, Checking the Cox model with cumulative sums of martingale-based residuals. Biometrika 1993 80 557 572
22. Ridker PM, MacFadyen JG, Everett BM, Libby P, Thuren T, Glynn RJ, CANTOS Trial Group Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: A secondary analysis from the CANTOS randomised controlled trial. Lancet 2018 391 319 328. doi: 10.1016/S0140-6736(17)32814-3
23. Ridker PM, Libby P, MacFadyen JG, Thuren T, Ballantyne C, Fonseca F, Koenig W, Shimokawa H, Everett BM, Glynn RJ, Modulation of the interleukin-6 signalling pathway and incidence rates of atherosclerotic events and all-cause mortality: Analyses from the Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS). Eur Heart J 2018 39 3499 3507. doi: 10.1093/eurheartj/ehy310
24. Kacimi R, Long CS, Karliner JS, Chronic hypoxia modulates the interleukin-1beta-stimulated inducible nitric oxide synthase pathway in cardiac myocytes. Circulation 1997 96 1937 1943
25. Van Tassell BW, Seropian IM, Toldo S, Mezzaroma E, Abbate A, Interleukin-1β induces a reversible cardiomyopathy in the mouse. Inflamm Res 2013 62 637 640. doi: 10.1007/s00011-013-0625-0
26. Kawaguchi M, Takahashi M, Hata T, Kashima Y, Usui F, Morimoto H, Izawa A, Takahashi Y, Masumoto J, Koyama J, Hongo M, Noda T, Nakayama J, Sagara J, Taniguchi S, Ikeda U, Inflammasome activation of cardiac fibroblasts is essential for myocardial ischemia/reperfusion injury. Circulation 2011 123 594 604. doi: 10.1161/CIRCULATIONAHA.110.982777
27. Hosenpud JD, Campbell SM, Mendelson DJ, Interleukin-1-induced myocardial depression in an isolated beating heart preparation. J Heart Transplant 1989 8 460 464
28. Jaiswal S, Natarajan P, Silver AJ, Gibson CJ, Bick AG, Shvartz E, McConkey M, Gupta N, Gabriel S, Ardissino D, Baber U, Mehran R, Fuster V, Danesh J, Frossard P, Saleheen D, Melander O, Sukhova GK, Neuberg D, Libby P, Kathiresan S, Ebert BL, Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease. N Engl J Med 2017 377 111 121. doi: 10.1056/NEJMoa1701719
29. Libby P, Ebert BL, CHIP (clonal hematopoiesis of indeterminate potential). Circulation 2018 138 666 668. doi: 10.1161/CIRCULATIONAHA.118.034392
30. Sano S, Oshima K, Wang Y, MacLauchlan S, Katanasaka Y, Sano M, Zuriaga MA, Yoshiyama M, Goukassian D, Cooper MA, Fuster JJ, Walsh K, Tet2-mediated clonal hematopoiesis accelerates heart failure through a mechanism involving the IL-1β/NLRP3 inflammasome. J Am Coll Cardiol 2018 71 875 886. doi: 10.1016/j.jacc.2017.12.037
31. Ridker PM, MacFadyen JG, Glynn RJ, Koenig W, Libby P, Everett BM, Lefkowitz M, Thuren T, Cornel JH, Inhibition of interleukin-1β by canakinumab and cardiovascular outcomes in patients with chronic kidney disease. J Am Coll Cardiol 2018 71 2405 2414. doi: 10.1016/j.jacc.2018.03.490